GuruTrack
TEVA

TEVA

TEVA PHARMACEUTICAL-SP ADR

Data as of 2026 Q1 (03-31) · 13F snapshot

Summary
TEVA PHARMACEUTICAL-SP ADR (TEVA) is held by 14 tracked hedge-fund managers, a combined reported value of ~$1.06B; the largest are Warren Buffett, Ken Griffin, Stanley Druckenmiller. This quarter: 3 new, 1 added, 2 trimmed, 1 closed. 9 members of Congress have disclosed STOCK Act trades. Data as of 2026 Q1, from public SEC 13F filings, delayed up to ~45 days.
Attention · HighThis quarter · Mixed
Gurus holding14
Congress trades9
Price$33.24vs quarter-end+10.36%
Sectors0
This quarter's moves
New3
Added1
Trimmed / sold3
Top holderWarren Buffett
Value $416.77M0.1% of portfolio42,789,2952021 Q3
Value $71.60M2.4% of portfolio2,377,2852026 Q1
David TepperBig trim
Value $69.80M1.2% of portfolio2,175,0002017 Q1
Value $58.20M— of portfolio1,932,4002026 Q1
Value $38.42M— of portfolio1,275,5002026 Q1
Value $36.05M0.9% of portfolio800,0002012 Q1
Value $18.20M— of portfolio604,2002026 Q1
Value $12.51M0.1% of portfolio277,5952009 Q1
Value $11.55M— of portfolio383,6002026 Q1
Value $2.36M— of portfolio78,2002026 Q1
Value $475.9K— of portfolio15,8002026 Q1
Value $241.3K0.1% of portfolio10,9502024 Q4
Value $80.0K— of portfolio10,0002021 Q4

Insider Trading

Officers · directors · Form 4
  • Matthew Shields

    EVP, Global Operations

    Sell$321.5K
    9,989 @ $32.19Traded 2026-06-18Filed 2026-06-22
  • Eliyahu Sharon Kalif

    EVP, Chief Financial Officer

    Sell$3.63M
    106,563 @ $34.10Traded 2026-06-11Filed 2026-06-16
  • Amir Elstein

    Director

    Buy
    14,492Traded 2026-06-05Filed 2026-06-08
  • Gerald M Lieberman

    Director

    Buy
    14,492Traded 2026-06-05Filed 2026-06-08
  • Sol J Barer

    Director

    Buy
    21,739Traded 2026-06-05Filed 2026-06-08
  • Ronit Satchi-Fainaro

    Director

    Buy
    14,492Traded 2026-06-05Filed 2026-06-08
  • Roberto Mignone

    Director

    Buy
    14,492Traded 2026-06-05Filed 2026-06-08
  • Tal Zvi Zaks

    Director

    Buy
    14,492Traded 2026-06-05Filed 2026-06-08
  • Chen Lichtenstein

    Director

    Buy
    14,492Traded 2026-06-05Filed 2026-06-08
  • Richard D Francis

    President and CEO

    Sell$211.4K
    6,153 @ $34.35Traded 2026-06-05Filed 2026-06-08
  • Perry Nisen

    Director

    Buy
    14,492Traded 2026-06-05Filed 2026-06-08
  • Rosemary A Crane

    Director

    Buy
    14,492Traded 2026-06-05Filed 2026-06-08
  • Richard D Francis

    President and CEO

    Buy
    13,043Traded 2026-06-05Filed 2026-06-08
  • Matthew Shields

    EVP, Global Operations

    Buy
    16,195Traded 2026-06-03Filed 2026-06-04
  • Matthew Shields

    EVP, Global Operations

    Sell$532.3K
    16,195 @ $32.87Traded 2026-06-03Filed 2026-06-04
  • Ronit Satchi-Fainaro

    Director

    Buy
    7,242Traded 2026-05-28Filed 2026-06-01
  • Chen Lichtenstein

    Director

    Buy
    7,242Traded 2026-05-28Filed 2026-06-01
  • Sol J Barer

    Director

    Buy
    10,863Traded 2026-05-28Filed 2026-06-01
  • Perry Nisen

    Director

    Buy
    7,242Traded 2026-05-28Filed 2026-06-01
  • Rosemary A Crane

    Director

    Buy
    7,242Traded 2026-05-28Filed 2026-06-01
  • Amir Elstein

    Director

    Buy
    7,242Traded 2026-05-28Filed 2026-06-01
  • Roberto Mignone

    Director

    Buy
    7,242Traded 2026-05-28Filed 2026-06-01
  • Gerald M Lieberman

    Director

    Buy
    7,242Traded 2026-05-28Filed 2026-06-01
  • Tal Zvi Zaks

    Director

    Buy
    7,242Traded 2026-05-28Filed 2026-06-01

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

ARK ETF holdings

Cathie Wood · daily
ARK total shares held · drag to inspect
2026-07-09holds 68,653
  • IZRLweight in fund1.64%$2.28M

ARK publishes full ETF holdings daily (SEC Rule 6c-11). Line shows ARK's total shares held over time (not price); markers are buy/sell days. Derived from public CSVs — research only, not investment advice.

Data from public SEC 13F & STOCK Act filings, delayed up to ~45 days, partial holdings only — for research, not investment advice.